Introductory Lecture: Allosteric Modulation of Torpedo Nicotinic Acetylcholine Receptor Ion Channel Activity by Noncompetitive Agonists

References

• Okonjo K. O., Kuhlmann J., Maelicke A. A second pathway of activation of the Torpedo acetylcholine receptor channel. Eur. J. Biochem. 1991; 200: 671–677
   PubMedGoogle Scholar
• Kuhlmann J., Okonjo K. O., Maelicke A. Desensitization is a property of the cholinergic binding region of the nicotinic acetylcholine receptor, not of the receptor-integral ion channel. FEBS Lett. 1991; 279: 216–218
   PubMed Web of Science ®Google Scholar
• Schrattenholz A., Godovac-Zimmermann J., Schäfer H.-J., Albuquerque E. X., Maelicke A. Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine. Eur. J. Biochem. 1993; 216: 671–677
   PubMedGoogle Scholar
• Schröder B., Reinhardt S., Schrattenholz A., McLane K. E., Kretschmer A., Conti-Tronconi B. M., Maelicke A. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor α-polypeptide. J. Biol. Chem. 1994; 269: 10407–10416
   PubMed Web of Science ®Google Scholar
• Shaw K. P., Aracava Y., Akaide A., Daly J. W., Rickett D. L., Albuquerque E. X. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonistic effects on the acetylcholine receptor-ion channel complex. Mol. Pharmacol. 1985; 28: 527–538
   PubMed Web of Science ®Google Scholar
• Albuquerque E. X., Aracava Y., Cintra W. M., Brossi A., Schönenberger B., Deshpande S. S. Structure-activity relationship of reversible cholinesterase inhibitors: Activation, channel blockade and stereospecificity of the nicotinic acetylcholine receptor-ion channel complex. Braz. J. Med. Res. 1988; 21: 1173–1196
   PubMed Web of Science ®Google Scholar
• Maelicke A., Coban T., Schrattenholz A., Schröder B., Reinhardt S., Storch A., Godovac-Zimmermann J., Methfessel C., Pereira E. F. R., Albuquerque E. X. Physostigmine and neuromuscular transmission. Ann. N. Y. Acad. Sci. 1993; 681: 140–154
   PubMed Web of Science ®Google Scholar
• Pereira E. F. R., Reinhardt S., Schrattenholz A., Maelicke A., Albuquerque E. X. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 1993; 265: 1474–1491
   PubMed Web of Science ®Google Scholar
• Pereira E. F. R., Alkondon M., Reinhardt S., Maelicke A., Peng X., Lindstrom J., Whiting P., Albuquerque E. X. Physostigmine and galanthamine characterize the presence of the novel binding site on the α482 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J. Pharmacol. Exp. Ther. 1994; 270: 768–778
   PubMed Web of Science ®Google Scholar
• Storch A., Schrattenholz A., Cooper J. C., Gutbrod O., Weber K.-H., Reinhardt S., Lobron C., Hermsen B., Soskic V., Pereira E. F. R., Albuquerque E. X., Methfessel C., Maelicke A. Physostigmine, galanthamine and codeine act as noncompetitive nicotinic receptor agonists on clonal rat pheochromocytoma cells. Eur. J. Pharmacol. 1995; 290: 207–219
   PubMed Web of Science ®Google Scholar
• Schrattenholz A., Pereira E. F. R., Roth U., Weber K.-H., Albuquerque E. X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 1996; 49: 1–6
   PubMed Web of Science ®Google Scholar
• Fels G., Plümer-Wilk R., Schreiber M., Maelicke A. A monoclonal antibody interfering with binding and response of the acetylcholine receptor. J. Biol. Chem. 1986; 261: 15746–15754
   PubMed Web of Science ®Google Scholar
• Albuquerque E. X., Pereira E. F. R., Castro N. G., Alkondon M., Reinhardt S., Schröder H., Maelicke A. Nicotinic receptor function in the mammalian central nervous system. Ann. N. Y. Acad. Sci. 1995; 757: 48–72
   PubMed Web of Science ®Google Scholar
• Reinhardt S., Schmiady H., Tesche B., Hucho F. Functional and structural analysis of acetylcholine receptor-rich membranes after negative staining. FEBS Lett. 1984; 173: 217–221
   PubMed Web of Science ®Google Scholar
• Prinz H., Veltel D. Variations in binding affinities of peripheral nicotinic acetylcholine receptor can be attributed to endogenous acetylcholine. Biol. Chem. Hoppe-Seyler 1988; 369: 1243–1249
   PubMed Web of Science ®Google Scholar
• Forman S. A., Miller K. W. Molecular sites of anaesthetic action in postsynaptic nicotinic membranes. Trends Pharmacol. Sci. 1989; 10: 447–452
   PubMed Web of Science ®Google Scholar
• Garty F., Rudy B., Karlish S. J. A simple and sensitive procedure for measuring isotope fluxes through ion-specific channels in heterogenous populations of membrane vesicles. J. Biol. Chem. 1983; 258: 13094–13099
   PubMed Web of Science ®Google Scholar
• Moore H.-P. H., Raftery M. A. Direct spectroscopic studies of cation translocation by Torpedo acetylcholine receptor on a time scale of physiological relevance. Proc. Natl. Acad. Sci. USA 1980; 77: 4509–4513
   PubMed Web of Science ®Google Scholar
• Riquelme G., Lopez E., Garcia-Segura L. M., Ferragut J. A., Gonzales-Ros J. M. Giant liposomes: A model system in which to obtain patch-clamp recordings of ionic channels. Biochemistry 1990; 29: 11215–11222
   PubMed Web of Science ®Google Scholar
• Johnston J. W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325: 529–531
   PubMed Web of Science ®Google Scholar
• McBain C. J., Mayer M. L. N-methyl-D-aspartic acid receptor structure and function. Physiol. Rev. 1994; 74: 723–760
   PubMed Web of Science ®Google Scholar
• Prinz H., Maelicke A. Ligand-binding to the membrane-bound acetylcholine receptor from Torpedo marmorata: A complete mathematical analysis. Biochemistry 1992; 31: 6728–6738
   PubMed Web of Science ®Google Scholar
• Prinz H., Maelicke A. Interaction of cholinergic ligands with the purified acetylcholine receptor protein. J. Biol. Chem. 1983; 258: 10263–10271
   PubMed Web of Science ®Google Scholar
• Hebb D. O. The organization of behaviour: A Neuropsychological Approach. John Wiley & Sons, Inc., New York 1949
   Google Scholar
• Schröder H., Giacobini E., Strubble R. G., Zilles K., Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging 1991; 12: 259–262
   PubMed Web of Science ®Google Scholar
• Whitehouse P. J., Martino A. M., Wagster M. V., Price D. L., Mayeux R., Atack J. R., Kellar K. J. Reduction in [3H]-nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: An autoradiographic study. Neurology 1988; 38: 720–723
   PubMed Web of Science ®Google Scholar
• Fambrough D. M., Drachman D. B., Styamurti S. Neuro-muscular junction in Myasthenia gravis: Decreased acetylcholine receptors. Science 1973; 182: 293–295
   PubMed Web of Science ®Google Scholar
• Maelicke A., Albuquerque E. X. New approach to drug therapy in Alzheimer's dementia. Drug Disc. Today 1996; 1: 53–59
   Web of Science ®Google Scholar
• Thal L. J., Fuld P. A., Masur D. M., Sharpless N. A. Oral physostigmine and lecithine improve memory in Alzheimer's disease. Ann. Neurol. 1983; 13: 491–496
   PubMed Web of Science ®Google Scholar